Guideline Recommendations for Continuation vs. Discontinuation of Antiviral Therapy in Chronic Hepatitis B

General Recommendation

In chronic hepatitis B patients receiving nucleos(t)ide analogues, therapy should be continued indefinitely until complete loss of hepatitis B surface antigen (HBsAg) is achieved; stopping earlier results in relapse in 50‑75 % of cases and may precipitate clinical decompensation, especially in HBeAg‑negative individuals and those with cirrhosis. [Strong consensus] 1

HBeAg‑Positive Patients

Primary endpoint: Continue therapy until HBsAg loss (with or without anti‑HBs seroconversion). [Strong consensus] 1
Alternative endpoint: Continue until HBeAg seroconversion together with undetectable HBV DNA, followed by at least 12 months of consolidation therapy before considering cessation. [Strong consensus] 2

HBeAg‑Negative Patients

Standard approach: Maintain antiviral therapy indefinitely; the only accepted stopping point is documented HBsAg loss. [Strong consensus] 3
Conditional alternative (not routinely advised): In selected patients, therapy may be stopped after ≥3 years of sustained virological suppression (undetectable HBV DNA on three separate tests ≥6 months apart); however, relapse occurs in 70‑75 % of such cases. [Strong consensus] 4
The American Association for the Study of Liver Diseases (AASLD) explicitly recommends lifelong treatment for HBeAg‑negative patients because of the risk of immune‑escape mutants and high relapse rates. [Strong consensus] 4

Patients with Cirrhosis

Compensated cirrhosis: Lifelong antiviral therapy is required; discontinuation is permissible only after confirmed HBsAg loss. [Strong consensus] 1
Decompensated cirrhosis: Indefinite (lifelong) therapy is mandatory; stopping is allowed only after HBsAg loss plus sustained anti‑HBs seroconversion for 6‑12 months. [Strong consensus] 3

Situations Where Discontinuation Is Contra‑Indicated

Patients with decompensated cirrhosis. [Strong consensus] 3
HBeAg‑negative patients who have not achieved HBsAg loss. [Strong consensus] 4
Compensated cirrhosis patients without HBsAg loss. [Strong consensus] 3
Individuals who were HBeAg‑positive at therapy initiation (high risk of severe relapse). [Strong consensus] 4

Management of Suboptimal Virological Response (Switch, Not Stop)

Low‑genetic‑barrier agents (e.g., lamivudine, telbivudine): Switch to high‑genetic‑barrier drugs such as entecavir or tenofovir. [Strong consensus] 5
Partial response to entecavir: Switch to tenofovir. [Strong consensus] 6
Virological breakthrough: Perform resistance testing and either add or switch to a non‑cross‑resistant antiviral. [Strong consensus] 7

Evidence Strength and Guideline Consensus (2020)

The Korean Association for the Study of the Liver (KASL), European Association for the Study of the Liver (EASL), AASLD, and Asian Pacific Association for the Study of the Liver (APASL) all concur that HBsAg loss is the optimal therapeutic endpoint. [Strong consensus] 1
AASLD adopts the most conservative stance, advocating indefinite therapy for HBeAg‑negative patients. [Strong consensus] 4
EASL permits consideration of treatment cessation after ≥3 years of sustained suppression in selected HBeAg‑negative patients, while emphasizing the high relapse risk. [Strong consensus] 4

Stopping Tenofovir in Hepatitis B: Guidelines and Recommendations

Primary Stopping Criteria by Patient Category

The American Association for the Study of Liver Diseases (AASLD) recommends that tenofovir should generally not be stopped in most patients with chronic hepatitis B, and discontinuation is only recommended after achieving HBsAg loss, with specific consolidation periods depending on HBeAg status and presence of cirrhosis 8, 9
For HBeAg-positive chronic hepatitis B, the preferred stopping criterion is HBsAg loss (with or without anti-HBs seroconversion) 8, 9
For HBeAg-negative chronic hepatitis B, the preferred stopping criterion is HBsAg loss (with or without seroconversion), although the AASLD recommends indefinite treatment for these patients due to high relapse rates 8, 9

Special Considerations for Cirrhosis

For patients with compensated cirrhosis, long-term (potentially lifelong) treatment is recommended, and discontinuation may only be considered after HBsAg loss 8, 10, 11
For patients with decompensated cirrhosis, indefinite (lifelong) treatment is mandatory, and treatment should never be stopped unless HBsAg loss and anti-HBs seroconversion is achieved and maintained for 6-12 months 8, 10, 11

Monitoring and Switching Treatment

If treatment is stopped (only after HBsAg loss), patients should be monitored with liver function tests every 1-3 months initially, HBV DNA measurement every 2-6 months, and HBsAg and anti-HBs checks every 6-12 months 12, 13
The European Association for the Study of the Liver (EASL) recommends switching from tenofovir to alternative agents (such as entecavir or tenofovir alafenamide) if tenofovir-associated renal dysfunction or bone disease occurs, or if the patient has risk factors for these conditions 11, 14

Guideline Recommendations for Discontinuation of Hepatitis B Antiviral Therapy

Universal Stopping Criterion

HBsAg loss (with or without anti‑HBs seroconversion) is the optimal endpoint for stopping antiviral therapy in all patient groups. This represents a functional cure and is the only universally accepted stopping point. 15, 16
After confirmed HBsAg loss, a consolidation phase of 6–12 months of continued antiviral therapy is advised before final discontinuation. 15

HBeAg‑Positive Patients

Standard Recommendation

Continue therapy indefinitely until HBsAg loss is achieved. This is the most conservative and safest approach. 15

Conditional Alternative (with significant caveats)

Therapy may be stopped after HBeAg seroconversion to anti‑HBe positivity together with undetectable HBV DNA, provided a 12‑month consolidation period is completed. 15, 16
Risk associated with this approach: approximately 38 % of patients develop ALT flares after cessation, the majority experience recurrent viremia, and relapse rates of 24–26 % are observed even after prolonged consolidation. 15
Prospective data show that all HBeAg‑positive patients who stopped therapy without HBsAg loss experienced virological relapse, and 75 % required retreatment. 15

Required Assessment Before Stopping (if HBsAg loss not achieved)

Patients must undergo liver biopsy or transient elastography to confirm only mild fibrosis (F0–F1). Those with fibrosis stage F2 or greater should remain on indefinite therapy. 15

HBeAg‑Negative Patients

Standard Recommendation (AASLD)

Indefinite (lifelong) therapy is required; the sole accepted stopping point is HBsAg loss. The American Association for the Study of Liver Diseases (AASLD) explicitly recommends lifelong treatment for this population because of high relapse rates and the risk of immune‑escape mutants. 15, 16

Conditional Alternative (selected patients)

Discontinuation may be considered after ≥3 years of sustained virological suppression (undetectable HBV DNA on three separate tests ≥6 months apart). Relapse occurs in 70–75 % of such cases. 16
This strategy demands extremely close post‑treatment monitoring and should be limited to patients who can guarantee rigorous follow‑up. 16
Longer on‑therapy remission improves outcomes: roughly 50 % maintain virological remission three years after stopping if they had >2 years of undetectable HBV DNA during treatment. 16

Patients with Cirrhosis

Compensated Cirrhosis

Lifelong antiviral therapy is mandatory; discontinuation is permissible only after confirmed HBsAg loss. Even after HBsAg loss, these patients require lifelong hepatocellular carcinoma (HCC) surveillance. 15, 16

Decompensated Cirrhosis

Indefinite therapy is absolutely required; stopping is contraindicated unless HBsAg loss plus sustained anti‑HBs seroconversion is maintained for 6–12 months. Overt hepatitis flares and life‑threatening episodes have been reported in cirrhotic patients who discontinue therapy. 16

Post‑Discontinuation Monitoring Protocol

Monitor ALT and HBV DNA monthly for the first 3 months after stopping, then every 3 months during the first year. 15

Retreatment Criteria

Restart antiviral therapy if HBV DNA rises to ≥2,000 IU/mL together with elevated ALT, or if there is any evidence of hepatic decompensation. 15

Special Populations

Older Adults

In patients older than 60 years, clinicians often continue therapy indefinitely unless HBsAg loss occurs, given the heightened risk of severe flares and limited life expectancy to achieve natural clearance. 17

Common Pitfalls to Avoid

Do not stop therapy in patients with significant fibrosis (F3) or any degree of cirrhosis (F4) unless HBsAg loss has been achieved. This is the most critical error to avoid. 15
Do not assume that HBeAg seroconversion guarantees a durable response; the majority of patients experience recurrent viremia after stopping. 15
Do not discontinue therapy abruptly without establishing a close monitoring plan, as hepatitis flares can be severe and life‑threatening. 16

Tenofovir Continuation Recommendations in Chronic Hepatitis B

Indefinite Therapy Recommendations

The American Association for the Study of Liver Diseases (AASLD) advises lifelong tenofovir therapy for HBeAg‑negative patients because relapse rates are high and immune‑escape mutants may emerge; treatment may only be stopped after documented HBsAg loss followed by 6–12 months of consolidation therapy. (strong guideline recommendation) 18
Both compensated cirrhosis and any decompensated cirrhosis constitute absolute indications for indefinite tenofovir therapy unless HBsAg loss is confirmed. (Class I recommendation) 19

Conditional Discontinuation Criteria

The European Association for the Study of the Liver (EASL) permits stopping tenofovir in highly selected non‑cirrhotic HBeAg‑negative patients who have ≥3 years of sustained virologic suppression (undetectable HBV DNA on three separate tests ≥6 months apart). This approach carries a 70–75 % relapse risk and requires intensive post‑cessation monitoring (monthly ALT and HBV DNA for the first 3 months, then every 3 months). It is not routinely advised and should be limited to patients able to guarantee strict follow‑up. (conditional recommendation) 19
The Korean Association for the Study of the Liver (KASL) recommends continuing tenofovir until HBsAg loss for HBeAg‑negative patients; for HBeAg‑positive patients, therapy should be maintained for at least 1 year after HBeAg seroconversion. (guideline consensus) 20

Safety and Switching Considerations

Tenofovir demonstrates an excellent long‑term safety profile: after 7 years of continuous use, 99.3 % of patients maintain viral suppression, grade 3/4 drug‑related adverse events occur in only ~1 % of patients, serum creatinine rises ≥0.5 mg/dL in 1.7 % of patients, and bone mineral density remains stable from year 4 to year 7. (observational data) — Note: this safety summary is derived from the article’s narrative and not linked to a specific citation.
For patients with renal impairment or osteoporosis risk, switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) is preferred over discontinuation, as TAF maintains antiviral efficacy with a more favorable renal and bone safety profile. (expert recommendation) 21

Guidelines for Discontinuation of Hepatitis B Antiviral Therapy

HBeAg‑Positive Patients – Conditional Discontinuation

In selected HBeAg‑positive individuals, therapy may be stopped after documented HBeAg seroconversion to anti‑HBe together with undetectable HBV DNA, provided that at least 12 months of consolidation therapy are completed. 22

HBeAg‑Negative Patients – Conditional Discontinuation

The European Association for the Study of the Liver (EASL) allows discontinuation in carefully selected non‑cirrhotic patients who have maintained undetectable HBV DNA on three separate measurements spaced ≥ 6 months apart for a minimum of 3 years. 22
Long‑term remission after stopping therapy is more likely when patients have achieved ≥ 2 years of continuous undetectable HBV DNA during treatment; approximately 50 % of such patients remain virologically suppressed three years after cessation. 22

Patients with Decompensated Cirrhosis

Indefinite antiviral therapy is required; discontinuation is only permissible after confirmed HBsAg loss together with sustained anti‑HBs seroconversion that persists for 6–12 months. 22
Reports indicate that abrupt cessation in cirrhotic patients can lead to overt hepatitis flares and life‑threatening episodes. 22

Post‑Discontinuation Monitoring Protocol

After stopping therapy, ALT and HBV DNA should be measured monthly for the first 3 months, then every 3 months throughout the first year. 22
Ongoing surveillance includes HBeAg/anti‑HBe testing every 3–6 months during the first year, HBV DNA and liver function tests every 3–6 months thereafter, and HBsAg/anti‑HBs assessment every 6–12 months to detect loss or reversion.

Patients should continue hepatocellular carcinoma surveillance every 6 months indefinitely, even after HBsAg loss.